Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
Myeloid Therapeutics
Incyte Corporation
Novartis
Avenzo Therapeutics, Inc.
Pfizer
Nurix Therapeutics, Inc.
Xencor, Inc.
858 Therapeutics, Inc.
Medicenna Therapeutics, Inc.
Lyell Immunopharma, Inc.
Dana-Farber Cancer Institute
Instituto do Cancer do Estado de São Paulo
Klus Pharma Inc.
Theratechnologies
University of Washington
Exelixis
University Health Network, Toronto
Stanford University
Cybrexa Therapeutics
Carisma Therapeutics Inc
Light Chain Bioscience - Novimmune SA
Salubris Biotherapeutics Inc
Valerio Therapeutics
Eli Lilly and Company
BioEclipse Therapeutics
Multitude Therapeutics Inc.
Pfizer
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
Xencor, Inc.
Ohio State University Comprehensive Cancer Center
Corcept Therapeutics
MacroGenics
Gilead Sciences
Jonsson Comprehensive Cancer Center
AIDS Malignancy Consortium
Abramson Cancer Center at Penn Medicine
City of Hope Medical Center
University of Washington
Alliance for Clinical Trials in Oncology
Pfizer
Albert Einstein College of Medicine
University of Chicago
Wake Forest University Health Sciences
Ohio State University Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
University of Washington
Wake Forest University Health Sciences
Fred Hutchinson Cancer Center
OHSU Knight Cancer Institute